Lilly fourth-quarter profit fall as generics hurt sales
Jan 29 (Reuters) - Eli Lilly and Co said on Tuesday that fourth-quarter earnings had fallen as competition from generic drugs drove revenue lower.
The U.S. drugmaker said it had earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.
Excluding special items such as asset impairments, restructuring and other special charges, Lilly earned 85 cents per share. Analysts on average were expecting 78 cents per share.
- U.S. war veteran released by North Korea returns home |
- South Korea to make announcement on air zone; expansion is anticipated |
- Pro-Europe protesters gather for rally in Kiev
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- Obama defends interim Iran deal, seeks to assure Israel